Gates Package — page 254

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Peter Stein, M.D. Director of Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Pamela Tenaerts, M.D., M.B.A. Executive Director, Clinical Trial Transformation Initiative Duke University Clinical Research Institute Peter Wung, M.D. Associate Vice President, Global OMD Lead, Immuno-Inflammation Sanofi Cli ical Trial Capacity Working Group Lionel Bascles, Ph.D. Senior Vice President, Global Head of Clinical Sciences & Operations Sanofi Myron Cohen, M.D. Associate Vice Chancellor for Global Health and Medical Affairs Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology Director, Institute for Global Health & Infectious Diseases University of North Carolina, Chapel Hill Lawrence Corey, M.D. Professor, Departments of Laboratory Medicine & Medicine Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences President & Director Emeritus Fred Hutchinson Cancer Research Center Victoria Davey, Ph.D., M.P.H. Associate Chief Research & Development Officer, Epidemiology and Public Health U.S. Department of Veterans Affairs Elizabeth Desrosiers, M.S., P.M.P. (Co-Chair) Executive Director, Clinical Sciences and Study Management Merck & Co., Inc. James Dickens Program Manager, Office of Rare Diseases Research National Center for Advancing Translational Sciences, NIH Jim Doroshow, M.D. Director, Division of Cancer Treatment and Diagnosis National Cancer Institute, NIH